icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (SURVEYOR-I)
 
 
  Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
 
Edward Gane1, Jacob Lalezari2, Armen Asatryan3, Susan Greenbloom4, Tarek Hassanein5, Teresa I Ng3, Ran Liu3, Chih-Wei Lin3, Jens Kort3, Federico J Mensa3 1Liver Unit, Auckland City Hospital, Auckland, New Zealand; 2eStudySite, San Diego, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Toronto Digesti ve Disease Associates, Toronto, Ontario, Canada; 5Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

EASL7

EASL8